• Ionis Begins ALS Clinical Trial americanpharmaceuticalreview
    October 28, 2020
    Ionis Pharmaceuticals announced the first patients have been dosed with ION541 (also known as BIIB105), an investigational antisense medicine being developed as a potential therapy to treat most forms of amyotrophic lateral sclerosis (ALS) regardless ...
PharmaSources Customer Service